… in the treatment of non-small cell lung cancer (NSCLC) have … advancing early detection and
multimodal care. The use of small … However, the overall cure and survival rates for NSCLC …

… cancer cases in the United States. After the initial diagnosis, accurate staging of non-small
cell lung cancer using … is crucial for determining appropriate therapy. When feasible, surgical …

… inhibitors as adjuvant therapy for resectable non-small-cell lung cancer now seems to be a
… cure rate. In a retrospective study of 167 patients with resectable non-small-cell lung cancer …

… Non-small cell lung cancer (NSCLC) is the most frequent cause of cancer death in the world,
… Therefore, new treatment approaches are needed. Targeting the epidermal growth factor …

… The WHO divides lung cancer into 2 major classes based on its biology, therapy, and
prognosis: NSCLC and small cell lung cancer (SCLC; see the NCCN Guidelines for Small …

… In the decade since the last Lancet Seminar on lung cancer there have been advances in
many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer (…

… validated for advanced non-small-cell lung cancer (NSCLC) in a second-line treatment setting.
… reported to have great efficacy in the first-line treatment of PDL1 ≥ 50% tumours (30% of …

… Oncology (ASCO) previously published evidencebased guidelines for the treatment of
unresectable non–small-cell lung cancer … ASCO practice guidelines for treatment of unresectable …

… Lung cancer is the leading cause of cancer-related death … been reached, so new treatment
strategies are clearly needed. … for the management of non–small-cell lung cancer. Monoclonal …

… Drugs approved by the FDA for the treatment of non-small-cell lung cancer. ALK, anaplastic
lymphoma kinase; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; …